Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer - Eli Lilly and Co (NYSE:LLY), Innovent Biologics (OTC:IVBIY), Innovent Biologics (OTC:IVBXF)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Innovent Biologics Inc (OTC:IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall survival (OS).
The trial assessed sintilimab in combination with chemotherapy (oxaliplatin and capecitabine) compared to chemotherapy alone in the first-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
In an interim analysis, the sintilimab - chemotherapy regime demonstrated a statistically significant improvement in OS compared to placebo plus chemotherapy in both the intention-to-treat (ITT) and PD-L1 positive groups.
No additional safety signals were identified.
The results will be presented at an upcoming medical meeting.
Based on the study's Independent Data Monitoring Committee recommendation, Innovent plans to review these results and file a supplemental marketing application of sintilimab in China.
Sintilimab, marketed as Tyvyt (sintilimab injection) in China, is a PD-1 inhibitor jointly developed by Innovent and Eli Lilly And Co (NYSE:LLY).

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!